3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model  by Paulitschke, Verena et al.
3,30,4,40,5,50-Hexahydroxystilbene Impairs Melanoma
Progression in a Metastatic Mouse Model
Verena Paulitschke1, Nikolaus Schicher1, Thomas Szekeres2, Walter Ja¨ger3, Leonilla Elbling4,
Angelika B. Riemer1, Otto Scheiner5, Golakoti Trimurtulu6, Somepalli Venkateswarlu6, Mario Mikula1,
Alexander Swoboda1, Edda Fiebiger7, Christopher Gerner4, Hubert Pehamberger1 and Rainer Kunstfeld1
Stilbenes comprise a group of polyphenolic compounds, which exert inhibitory effects on various
malignancies. The aim of this study was to evaluate the antitumor effects of a previously unreported stilbene
derivative—3,30,4,40,5,50-hexahydroxystilbene, termed M8—on human melanoma cells. Cell-cycle analysis of the
metastatic melanoma cell line M24met showed that M8 treatment induces G2/M arrest accompanied with a
dose- and time-dependent upregulation of p21 and downregulation of CDK-2 and leads to apoptosis. M8
induces the expression of phosphorylated p53, proteins involved in the mismatch repair machinery (MSH6,
MSH2, and MLH1) and a robust tail moment in a comet assay. In addition, M8 inhibited cell migration in Matrigel
assays. Shotgun proteomics and western analysis showed the regulation among others of paxillin, integrin-
linked protein kinase, p21- activated kinase, and ROCK-1 indicating that M8 inhibits mesenchymal and
amoeboid cell migration. These in vitro data were confirmed in vivo in a metastatic human melanoma severe
combined immunodeficient (SCID) mouse model. We showed that M8 significantly impairs tumor growth. M8
also interfered with the metastatic process, as M8 treatment prevented the metastatic spread of melanoma cells
to distant lymph nodes in vivo. In summary, M8 exerts strong antitumor effects with the potential to become a
new drug for the treatment of metastatic melanoma.
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INTRODUCTION
The incidence of melanoma has increased more rapidly than
that of any other malignancy over the past 10 years and is
responsible for 80% of deaths from skin cancer (Miller and
Mihm, 2006). Metastatic melanoma is associated with poor
prognosis and a median survival time of only 7.5 months. The
median survival time has not improved during the past 20
years, which may be attributable to the disappointingly low
response rate of this malignancy to chemotherapy. Taken
together, these facts underscore the urgent need for new
therapeutic approaches in the treatment of metastatic
melanoma.
Promising new candidates for melanoma therapy are
stilbenes with resveratrol as the lead drug. Resveratrol
has well-studied effects on the cardiovascular system and
shows promising activity against various malignancies
such as colon and prostate cancers. Antitumor effects of
resveratrol in vitro can be explained by the interference of
the drug with several mechanisms important for tumor
progression and survival. Cell-cycle arrest and induction of
apoptosis through the activation of Bax and Bak, cytochrome
c release and subsequent caspase activation, antiangiogenic
effects, and modulation of the mismatch repair (MMR)
machinery are reported in the literature (Hsieh et al.,
1999).
Notably, resveratrol treatment activates p53, which results
in cell-cycle arrest in the S and G2 phases as well as induction
of apoptosis in melanoma (Hsieh et al., 2005) and endothelial
cells (Hsieh et al., 1999). Furthermore, p53 was recognized
as a major component of the DNA damage response pathway
(Lane, 1992; Levine, 1997). DNA damage induces phosphor-
ylation of p53 at Ser15 and Ser37 and leads to reduced
interaction of p53 with its negative regulator, the oncoprotein
MDM2 (Shieh et al., 1997). Different types of p53-induced
DNA repair pathways exist—such as the MMR and the
double-strand breaks repair pathway (Houtgraaf et al., 2006).
DNA damage response mechanisms maintain genomic
stability in normal cells. Because genomic instability is a
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hallmark of cancer cells, it is obvious that at least some of
these damage response pathways are affected during cancer
progression.
The MMR pathway is involved in the repair of base
mismatches, small insertions, or deletions of nucleotides.
Activation of the MMR system either leads to repair of certain
DNA defects during the G2/M phase cell-cycle checkpoint or
induces apoptosis in irreparably damaged cells (Hawn et al.,
1995; Brown et al., 1997; Davis et al., 1998), whereas loss of
the MMR has been shown to be important in the develop-
ment of cancer (Buermeyer et al., 1999). Davis et al. (1998)
have hypothesized that the MMR system binds and recog-
nizes certain lesions, resulting in the formation of DNA
breaks. These breaks produce a signal that results in G2/M
phase arrest and a loss of survival signals. Consistently, p53
has been linked to the MMR pathway (Duckett et al., 1999),
because the MMR proteins such as MutS homologue 2
(MSH2) or MtL homologue 1 (MLH1) are known to be p53
target genes (Scherer et al., 2000; Warnick et al., 2001; Chen
and Sadowski, 2005).
Very recently, p53 was also shown to regulate cell motility
and actin cytoskeletal organization suggesting that p53 might
be involved in tumor invasion and metastasis. The effects of
p53 on cell migration are largely mediated by reorganization
of the actin cytoskeleton through Rho GTPases. Three main
classes of Rho GTPases—Rac, Cdc42, and Rho—control cell
protrusions during migration. Rac promotes the formation of
membrane extensions at the leading edge of the cell, called
lamellipodia, Cdc42 generates the formation of filopodia, to
sense the surrounding extracellular environment and ROCKs
(Rho kinases), key effectors of RhoA and RhoC, cause the
formation of actin stress fibers and focal adhesions generating
an amoeboid movement (Sahai and Marshall, 2003). Rac,
Cdc42, and Rho activate two downstream kinases, p21-
activated kinase (PAK) and ROCK. p53 was shown to
function upstream of ROCK as a negative regulator of ROCK
inhibiting cell migration (Qin et al., 2009). Cancer cell
migration can convert between the mesenchymal and
amoeboid types. Remodeling of the extracellular matrix is
required for mesenchymal migration. In contrast, cancer cells
change to amoeboid migration in the presence of protease
inhibitors and migrate through the extracellular matrix.
Therefore cancer cell migration cannot be repressed only
by protease inhibitors because cancer cells have also the
ability for mesenchymal invasion. To regulate cancer cell
migration, both types of migration should be repressed
simultaneously.
Resveratrol was described to be an effective inhibitor of
ribonucleotide reductase and was also shown to block
cyclooxygenases (COX-1, COX-2), which can promote tumor
growth (Murias et al., 2004; Horvath et al., 2006). COX-2 has
already been suggested as a potential target for the treatment
of melanoma (Wilson, 2006).
Despite these promising effects of resveratrol in vitro, the
in vivo activity on several tumor entities, including melano-
ma, has been disappointing (Niles et al., 2006). Therefore,
previously unreported derivates of resveratrol are actively
investigated. 3,30,4,40,5,50-Hexahydroxystilbene (M8) is a
hydroxyl derivative of the parent compound resveratrol. This
drug modification results in enhanced antioxidant and
antitumor effects in promyelocytic leukemia cells when
compared with resveratrol (Horvath et al., 2006; Saiko
et al., 2006). Although resveratrol exerts a nonselective
inhibition of COX-1 and COX-2, M8 is a highly selective
inhibitor of COX-2 recommending its application for
melanoma treatment. Notably, M8 has a higher selectivity
index for COX-2 than even rofecoxib or celecoxib (Murias
et al., 2004, 2005). In this study we evaluated the antitumor
effects of M8 on melanoma in vitro and in vivo.
RESULTS
M8 reduces cell proliferation through cell-cycle arrest and
induction of apoptosis in vitro
We first compared M8 and resveratrol for their effects on cell
proliferation on M24met melanoma cells in vitro. As
determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt) proliferation assays, the IC50 of M8 is in a range
between 20 and 25 mM after 48 hours. Even at a four times
higher dose (100 mM), resveratrol was not able to inhibit
melanoma cell growth by half (compare Figure 1a and b). We
next isolated M24met cells from xenografts to compare the
effects of both compounds on cell proliferation of in vivo
propagated melanoma cells. These xenografted M24met cells
showed generally a more aggressive growth rate when
compared to in vitro cultures of M24met (compare Figure a
and b vs c and d). On isolated M24met clones, M8 showed
an IC50 of approximately 25 mM after 48 hours. In contrast to
M8, resveratrol did not impair cell proliferation at that time
point at all (compare Figure 1c and d). Furthermore we
confirmed the antiproliferative effect of M8 in the metastatic
melanoma cell line 1205Lu, in primary human melanoma
cells (MCM1, MCM19, and MLNM1) and in another tumor
entity, namely, the gastric cancer cell line MKN28. In all
listed tumor cells M8 was found to be superior to resveratrol
(Table 1). Importantly, the cell growth of primary, not
transformed, melanocytes was not influenced by M8 (data
not shown). We therefore concluded that the antiproliferative
effects of M8 are restricted to malignant cells and that M8 is
superior to resveratrol in vitro.
To further elucidate the antiproliferative mechanism of M8
we evaluated cell-cycle alterations mediated by M8 in the
M24met melanoma cell line. The number of cells arrested in
G2/M doubled in treated compared with untreated cultures
after 24 hours of M8 incubation (Figure 2a and b). p21, a
transcriptional target of p53, is known to induce S phase or
G2/M arrest through inhibition of cyclin-dependent kinases
(CDKs) (Harper et al., 1993; Xiong et al., 1993). M8 led to a
dose- and time-dependent induction of p21 (Figure 2c). At
4 hours after M8 treatment an upregulation of p21 protein
levels could be observed. p21 induces cell-cycle arrest
through inhibition of CDK-2. We therefore studied the
potential effects of M8 on CDK-2. M8 treatment resulted in
a downregulation of CDK-2 at a concentration of 50mM
(Figure 2d). These observations are in line with previous data
showing that resveratrol causes G1, S phase, as well as G2/M
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arrest depending on the cell system used (Ragione et al.,
1998; Delmas et al., 2002).
Resveratrol has been also reported to exert antiprolifera-
tive activity by inducing apoptosis (Huang et al., 1999). To
evaluate the proapoptotic potential of M8, we performed
Annexin V staining on M8-treated cells. Annexin V flow
cytometry analysis revealed a significant increase (Po0.05)
of apoptotic cells (Figure 3a). Whereas resveratrol failed to
induce apoptosis at a concentration of 50 mM (Figure 3b), the
mean of apoptotic cells doubled after M8 treatment with
the same concentration (Figure 3b). In line with this finding
we show a dose-dependent induction of the proapoptotic
proteins Bak and cleaved caspase-3 after 48 hours of
incubation (Figure 3c). In summary, the combination
of inhibition of cell growth, G2/M arrest, and induction of
apoptosis by M8 is responsible for the strong antiproliferative
effect of this drug in vitro. The direct comparison of M8 and
resveratrol effects showed that M8 is more effective in all
pathways analyzed.
M8 treatments induces DNA damage, p53, and the mismatch
repair machinery in vitro
On the basis of evidence in proteomic analysis (manuscript in
preparation) that M8 leads to DNA damage, we analyzed the
regulation of the p53 pathway. DNA damage induces
phosphorylation of p53 at Ser15 and Ser37 (Scherer et al.,
2000). Western blot analysis of M8-treated M24met cells at
the IC50 (25 mM) showed a robust induction of p53ser15 and
p53ser37, but no major regulation of total p53 (Figure 4a).
MSH2, MLH1, and MutS homologue 6 (MSH6) were
identified as p53 target genes and link p53 to the MMR
pathway (Scherer et al., 2000; Warnick et al., 2001; Chen
and Sadowski, 2005). In line with the previous results, M8
treatment was found to induce MSH6, MSH2, and MLH1
expression in a dose-dependent manner (12.5–25 mM; Figure
4a). In primary melanocyte cultures, M8 did not induce
proteins of the MMR machinery (Supplementary Figure S2).
Furthermore, we assessed M8-induced DNA damage
in a comet assay (Tice et al., 2000). M8 treatment induced
DNA damage rapidly within 5minutes of incubation in a
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Figure 1. M8 is superior to resveratrol in inhibiting growth of the human melanoma cell line M24met. (a, b) Cell viability and proliferation assay. M24met
human melanoma cells were treated with 3,30,4,40,5,50-hexahydroxystilbene (M8), resveratrol (Res) (6.25, 12.5, 25, 50, and 100 mM) or a solvent control (DMSO)
for 24, 48, and 72 hours. Points, mean of three independent experiments performed in quintuplicates; bars, SD. (c, d) M24met melanoma cells propagated
in vivo were derived from two mice, isolated, and treated with the indicated concentrations of M8, resveratrol, or solvent control. Results from one
representative cell line are shown.
Table 1. Unpaired t-test
Entity Cell line Treatment IC50
Significance
(P-value)
Melanoma cell line
of lung metastasis
1205Lu M8 12.13 0.0160
1205Lu Resveratrol 46.31
Primary melanoma of
cutaneous metastasis
MCM1 M8 29.65 0.0139
MCM1 Resveratrol 98.21
Primary melanoma of
cutaneous metastasis
MCM19 M8 21.09 0.0038
MCM19 Resveratrol 92.89
Primary melanoma
of lymph node
metastasis
MLNM1 M8 66.79 0.0689
MLNM1 Resveratrol 97.18
Gastric cancer (tubular
adenocarcinoma)
MKN28 M8 28.99 0.0277
MKN28 Resveratrol 174.1
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dose-dependent manner. In the same setting, resveratrol
showed only slightly effects. M8 induced a 1.77-fold increase
of the tail moment at 25 mM, a 3.63-fold increase at 50 mM,
and a 9.25-fold increase at 100mM, with a maximum 9.96-
fold increase at 200mM (Figure 4b). Over the whole
concentration range, resveratrol had little effect. Resveratrol
only led to a 1.35-fold increase at the highest concentration
of 200mM. H2O2 was used as a positive control leading to a
27.56-fold increase of the tail moment after 5minutes (Figure
4b). Cell viability at the time of assay was consistently above
90%. This set of data confirm that treatment with M8 leads to
p53 and MMR machinery activation by the induction of DNA
damage.
M8 reduces migratory properties of M24met in vitro through
interference with the p53 pathway and paxillin
To further elucidate the effects of M8 treatment on the
migratory properties of M24met cells, we performed
western blot analysis and observed that M8 treatment
downregulated ROCK-1 expression (Supplementary Figure
S3). This finding is consistent with the experiments that show
upregulation of p53 by M8. In striking contrast, resveratrol
resulted in an upregulation of ROCK-1 (Supplementary
Figure S3), suggesting that resveratrol is not able to block
migration through this pathway.
PAK is a one of the best known downstream targets of
Cdc42 and Rac and serves as primary binding partner for Pix
(PAK-interactive exchange actor). Pix belongs to the family of
PAK-binding proteins that has strong regulatory effects on
PAK function involved in alterations in the actin cytoskeletal
architecture (Feng et al., 2002). A variety of proteins are
involved in the regulation of cell migration. To screen for
several proteins at once, we performed shotgun proteomics
with M8-treated and -untreated M24met and 1205Lu
melanoma cells. Label-free relative quantification was
performed using a spectrum counting method as described
(Wimmer et al., 2009). Thus we were able to show that M8
regulates PAK and Pix expression (Table 2). In addition, M8
led to a downregulation of integrin-linked kinase (ILK)-1 in
both metastatic melanoma cell lines, M24met and 1205Lu
(Table 2). The ILK is required for the activation of Rac and
Cdc42 through Pix and is essential in Rac- and Cdc42-
mediated actin cytoskeleton reorganization, suggesting that
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Figure 2. M8 induces G2/M arrest through inhibition of CDK-2 and
induction of p21. (a, b) Cell-cycle analysis by flow cytometry using propidium
iodide (PI)-stained M24met. Cells were treated for 24 hours with 25 mM
3,30,4,40,5,50-hexahydroxystilbene (M8). (a) One representative DNA
histogram of cell-cycle analysis of M24met treated with M8, with PI staining
shown on the x axis and counts given on the y axis. (b) Three independent
experiments were pooled and analyzed as a combined data set. (c) M8 leads
to an induction of p21 over time. Immunoblotting of p21 after 4, 8, 24, and
48hours of M8 treatment with indicated concentrations (12.5–50mM). (d) Cell
lysates of M24met melanoma cells were subjected to immunoblotting for
CDK-2 after 48 hours of M8 treatment.
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Figure 3. M8 treatment induces apoptosis in M24met cells. (a) 3,30,4,40,5,50-
Hexahydroxystilbene (M8)-induced apoptosis as shown in the representative
example of Annexin V flow cytometry analysis with the x axis showing
Annexin V staining and the y axis 7-amino-actinomycin D (7-AAD) and
phycoerythrin (PE) staining. (b) Summary of Annexin V assays analyzing
M24met melanoma cells treated with 25 and 50 mM M8 and 50 mM resveratrol.
The sum of the percentages of Annexin V and 7-AAD-PE-positive cells was
calculated. Three independent experiments were pooled and analyzed as a
combined data set. Columns, mean of three independent experiments; bars,
SEM; asterisk, significance as determined by unpaired t-test. *Po0.05. (c) Cell
lysates of M24met melanoma cells were subjected to immunoblotting for
caspase-3 (band represents cleaved caspase-3 at 17 kDa) and Bak after
48 hours of M8 treatment. Indicated concentrations are in mM.
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ILK regulates cancer motility and invasiveness (Filipenko
et al., 2005). The initiation of filopodia requires activation of
Cdc42, which in turn recruits and activates the Arp2/3
complex (Welch and Mullins, 2002; Svitkina et al., 2003).
Consistently, M8 downregulated the Arp2/3 complex in both
melanoma cell lines (Table 2).
In addition, a key regulator of cell migration, paxillin, was
as well found to be regulated in M24met and 1205Lu
melanoma cell lines (Table 2).
P21, the known activator of PAK, may indirectly affect
cytoskeletal organization and cell migration through regula-
tion of the Rho pathway (Heckman et al., 2009) and is
involved in cell-cycle progression. Therefore p21, verified to
be affected by M8 with western blotting and shotgun
proteomics, provides an important interference partner for
the compound M8.
We performed a Matrigel invasion chamber assay to show
the consequences of M8-dependent ROCK and paxillin
regulation for cell migration. M8 blocked cell migration at
25 mM after 48 hours (Figure 4c) with Po0.0015 as evaluated
by computer-assisted analysis. In contrast, resveratrol did not
influence cell migration in the same setting (data not shown).
In summary, M8 leads to DNA damage and the
subsequent activation of p53 and its transcriptional targets
and to an inhibition of mesenchymal and amoeboid cell
migration (Figure 4d).
M24met
0 12.5 25 50 M8 (μM)
(μM)
M8 Res
H
2O
2
M8 (25 μM)
250 μm
250 μm
MSH 6
100
75
50
25
0T
ai
l m
om
en
t (a
rbi
tra
ry 
un
its
)
0 5 10 25 2550 5010
0
10
0
20
0
20
0
MSH 2
MLH 1
Actin
Actin
Actin
Control
Actin
p53ser15
p53
M8 OH
OH
OH
HO
HO
HO
Ser 15 Ser 37
p53
p21
MSH2 MSH6 MLH1
Bak Caspase 3
Mismatch repair
Cell migration
Apoptosis DNA damage
IIk-1
Pak Paxillin
ROCK
AmoeboidMesench.
Arp 2/3
RhoGAP
Rho
GAPases
α-Pix
(cool-2)Cell cycle arrest (G2/M)
CDK2 Transcriptional activation
p53ser37
Figure 4. M8 treatment leads to DNA damage, induces p53 phosphorylation, and the mismatch repair machinery. (a) Representative immunoblots of
three independent experiments of MSH6, MSH2, MLH1, p53ser37, p53ser15, and p53 after 48 hours treatment of 3,30,4,40,5,50-hexahydroxystilbene (M8) with
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M8 reduces tumor growth and exerts antiproliferative activity
in vivo
So far our findings showed that the antineoplastic activity of
M8 was superior to the parent compound resveratrol in vitro.
Thus we next wanted to analyze whether M8-induced
antitumor effects also translated to in vivo models of
metastatic melanoma. For that aim, we used a spontaneously
metastatic human melanoma mouse model.
Treatment with M8 (2.5 and 5mgkg1 per day) was
started after the animals had developed palpable tumors.
Notably, 2.5mg kg1 is approximately equivalent to 25mM
(IC50 in vitro) and 5mg kg
1 to 50 mM. After 10 days of
therapy, primary tumors were excised. In the control group
mean tumor volumes were 1,454mm3 compared to 754mm3
(Po0.01) in the 2.5mg kg1 per day group and to 671mm3 in
the 5mg kg1 per day group (Po0.001) (Figure 5a and b). We
performed another set of experiments applying equal doses of
M8 twice a day (2.5 and 5mg kg1 per 2 days), which yielded
a comparable effect to a single daily application on tumor
progression (data not shown).
To evaluate potential antiproliferative effects of M8 on
tumor cells, we subjected nodular melanomas to immuno-
histochemical staining of the proliferation-associated marker
Ki-67. Computer-assisted analysis of the Ki-67-positive cells
in each group revealed a significant reduction both in the
2.5mg kg1 per day (Po0.01) and in the 5mg kg1 per day
group (Po0.01) (Figure 5c and d). The percent of Ki-67-
positive cells per field was reduced from 4.2% in the control
group to 1.2% in the 2.5mg kg1 per day treatment group
and to 1.1% in the 5mg kg1 per day group. In conclusion,
M8 exerted profound antiproliferative effects on melanoma
cells in vivo.
M8 treatment reduces metastasis to distant lymph nodes
Development of metastasis is a critical step in melanoma
progression. To evaluate the effect of M8 on metastasis, we
continued treatment for another 10 days after primary tumor
excision. Then, animals were sacrificed and axillary and
inguinal lymph nodes were analyzed. The average weight of
the lymph nodes was reduced in a dose-dependent manner in
the treatment groups indicating that M8 reduces metastasis.
The average weight of the lymph nodes was 0.75mg in the
control group, 0.3mg in the 2.5mg kg1 group, and 0.3mg in
the 5mg kg1 group (Figure 6a). To confirm these results, we
also calculated the lymph node volume and observed a
significant reduction (P¼ 0.011) in the M8-treated groups
(Figure 6b). To elucidate if the reduction of the lymph node
volume and weight in the M8-treated groups is caused by a
reduced metastasis, we used immunohistochemical staining
with a vimentin antibody to visualize single melanoma cells
or clusters of metastatic melanoma cells (Loewe et al., 2006).
We defined grade 0 as a lymph node without metastasis,
grade 1 with metastasis of single cells typically occurring only
in the cortex of the lymph nodes, grade 2 with metastasis
filling more than 50% of the lymph node, and grade 3 with
full repletion with melanoma cells (for histological examples,
see Supplementary Figure S4). The mean grade in the control
group was found to be 2.3 (equivalent to approximately 80%
metastasis in the lymph nodes) whereas the mean grade in
the 2.5mg kg1 group and in the 5mg kg1 group found
Table 2. Chi-square test
AccNr Protein MW pI
M24met
control
M24met
25lM M8 Regulation
1205Lu
control
1205Lu
25lM M8 Regulation
Q92747 Actin-related protein 2/3 complex subunit 1A (Arp 2/3) 41,570 8.46 1 0 1 P¼ 0.073 — — —
O15143 Actin-related protein 2/3 complex subunit 1B (Arp 2/3) 40,819 8.69 1 1 0 2 0 2 P¼ 0.017
P38936 Cyclin-dependent kinase inhibitor 1 (p21) (CDK-
interacting protein 1) (melanoma differentiation-
associated protein 6)
17,988 8.69 0 1 1 P¼ 0.006 — — —
Q13418 Integrin-linked protein kinase (ILK-1) (ILK-2) 51,420 8.3 2 1 1 P¼ 0.025 1 0 1 P¼ 0.317
P49023 Paxillin 64,534 5.73 3 1 2 P¼ 0.044 1 0 1 P¼ 0.047
Q15052 Rho guanine nucleotide exchange factor 6 (Rac/Cdc42
guanine nucleotide exchange factor 6) (PAK-interacting
exchange factor alpha) (Alpha-Pix) (COOL-2)
87,499 5.79 1 0 1 P¼ 0.022 — — —
Q07960 Rho-GTPase-activating protein 1 (GTPase-activating
protein rhoOGAP) (Rho-related small GTPase
protein activator) (CDC42 GTPase-activating protein)
(p50-RhoGAP)
50,436 5.85 1 3 2 P¼ 0.087 — — —
P98171 Rho-GTPase-activating protein 4 (Rho-GAP
hematopoietic protein C1)
105,056 5.91 — — — 0 1 1 P¼ 0.023
Q13153 Serine/threonine-protein kinase PAK 1 (p21-activated
kinase 1) (PAK-1)
60,647 5.55 — — — 1 0 1 P¼ 0.055
Q13177 Serine/threonine-protein kinase PAK 2 (p21-activated
kinase 2) (PAK-2)
58,005 5.7 4 1 3 P¼ 0.12 2 0 2 P¼ 0.021
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Figure 5. Antiproliferative effects of 3,30,4,40,5,50-hexahydroxystilbene (M8) on M24met melanoma growth in vivo. M24met melanoma cells were implanted
subcutaneously into the flank of severe combined immunodeficient (SCID) mice. Treatment (daily, intraperitoneal) started after clinical appearance of tumors.
Tumors were excised at day 10, and the experiment was terminated at day 20. (a) Development of tumor size during therapy with indicated concentrations.
Points, mean; bars, SD. (b) Tumor volume at the day of excision. Bars, SD. (c) Immunohistochemistry of M24met tumors with anti-human Ki-67 antibody
(brown, indicated with arrows). (d) Computer-assisted quantification of Ki-67-positive cells per 10 high-power fields. Columns, mean; bars, SEM; asterisk,
significance as determined by unpaired t-test. **Po0.01; NS, not significant.
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Figure 6. M8 reduces metastasis in distant lymph nodes. Lymph nodes derived from the M24met tumor-bearing mice were examined for their weight
and stained with hematoxylin and eosin and for human vimentin. (a) Weight of the axillary and inguinal lymph nodes in control and treated animals;
(b) volume of the axillary and inguinal lymph nodes, mean; bars, SEM; (c) mean of the grade defining the vimentin-positive staining in each group; (d) summary
of percent of macrometastasis and micrometastasis in lymph nodes of 3,30,4,40,5,50-hexahydroxystilbene (M8)-treated and control animals. Significance as
determined by Kruskal–Wallis test. *Po0.05.
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to be around 1.5 (equivalent to approximately 45%
metastasis in the lymph nodes) (Figure 6c). The mean
difference of 0.8 from grade 2.3 to grade 1.5 reflects almost
a bisection of metastasis. All 10 control mice had lymph
node metastasis, with 2 mice showing metastasis on both
axillary lymph nodes and the right inguinal side. In the
control group 71.4% of all lymph nodes were vimentin
positive (Figure 6d). Only 41.2% of the lymph nodes of 10
mice treated with 2.5mg kg1 per 2 days revealed to be
vimentin positive (Figure 6d). Comparable results were
achieved in the group receiving 5mg kg1 M8. No mouse
in the treatment groups reached the inguinal stage of
metastasis whereas 56% of the animals in the untreated
control group did. We conclude that treatment with M8 leads
to a reduction of metastasis to distant lymph nodes and might
therefore serve as a potent drug targeting metastasis, the
critical step in tumor progression.
DISCUSSION
To the best of our knowledge, a systematic effort to assess the
anticancer mechanisms of the stilbene derivative M8 on
melanoma is previously unreported. Here we show that M8
exerts pronounced antitumor effects and is superior to
resveratrol in inhibiting growth as well as rate of metastasis
of melanoma in vitro and in vivo. We show that M8 interferes
with several pathways involved in apoptosis, cell-cycle
regulation, DNA damage repair, cell migration, and metas-
tasis. We show that M8 induces DNA damage through the
activation of DNA repair systems such as the MMR pathway.
Consistently, p53 was found to be activated and led to a
transcription of a subset of apoptotic proteins and of cyclin-
dependent kinase inhibitors interfering with the cell cycle. In
line with our data, M8 has recently been shown to induce
p53 in breast cancer cells (Murias et al., 2008). Moreover, M8
impaired cell migration by regulating the Rho pathway.
Antineoplastic effects were further shown in an in vivo model,
where treatment with M8 led to a reduction of tumor growth
and metastasis. Our study shows for the first time that M8 is
able to interfere with these pathways. The data point to M8 as
a new attractive candidate for therapy of human melanoma.
In detail, M8 was found to be more effective than
resveratrol on the M24met melanoma cell line, M24met
cells isolated ex vivo, the metastatic cell line 1205Lu, primary
human melanoma cells isolated out of cutaneous and lymph
node metastasis, and also in another tumor entity as
demonstrated in gastric cancer. These results are in line with
recent studies showing the superior anticancer properties of
M8 on HL-60 human promyelocytic leukemia cells in
comparison to resveratrol (Horvath et al., 2006; Saiko et al.,
2006). Resveratrol is currently tested in clinical phase I and
phase II trials for the treatment of colon cancer, advanced
lymphoma, and as a cancer chemoprevention drug. Owing to
the similar structural formula, but a superior efficacy as
shown in this study, M8 might serve as a more potent
anticancer drug.
Consistent with the M8-mediated p53 activation, M8
induces the expression of transcriptional targets of activated
p53, such as p21 (mediating cell-cycle arrest), Bax, and
processed caspase-3 (leading to apoptosis). In flow cytometry
analysis we were able to confirm these results showing that M8
promotes G2/M cell-cycle arrest and leads to an induction of
Annexin-V-positive cells. Moreover, M8 induced proteins of
the MMR machinery, which are known to be activated by p53
in response to DNA damage. In addition, M8 also leads to a
total inhibition of tumor cell migration in a Matrigel assay.
Importantly, paxillin is regulated in both metastatic
melanoma cell lines M24met and 1205Lu as shown by
shotgun proteomics. Paxillin has emerged as a key coordi-
nator of proteins of the Rho GTPase family and their signaling
cascades in the context of cell spreading and migration. It is
one of the earliest proteins that is recruited to focal adhesions
and is necessary for their turnover during cell migration.
Paxillin directly interacts with the ILK and PAK, both of which
are downregulated in M24met and 1205Lu melanoma cell
lines by M8 treatment. In addition paxillin recruits the
PAK–PIX complex (Deakin and Turner, 2008), suggesting that
M8 inhibits the paxillin-dependent formation of the PAK–PIX
complex. Thus M8 appears to interfere with ILK-1 signaling
and to inhibit Arp2/3 activity that regulates mesenchymal
invasion. Conversely, ROCK-1, which is crucial for amoe-
boid invasion, was found downregulated by M8. Thus, M8
appears to interfere with both the mesenchymal and
amoeboid migration showing the high efficacy in this critical
step of tumor progression.
M8 exerts robust antitumor activity, but cytotoxicity
toward healthy tissue is rather unlikely as there is neither
antiproliferative activity on melanocytes nor an induction of
MMR proteins in healthy cells. These results indicate that M8
selectively inhibits the growth of malignant cells.
We were able to confirm our in vitro data in a metastasizing
mouse model in vivo. In this model, M8 impairs tumor
progression and reduces metastasis to the distant lymph nodes.
The local invasion and metastatic spread are responsible
for the morbidity and mortality in human melanoma. Despite
recent important advances in the adjuvant treatment of stage
III tumors, little has changed in the management of advanced
metastatic disease. A number of chemotherapeutic agents
show some benefit in patients with metastatic melanoma,
including dacarbazine, nitrosoureas, platinum analogues,
vinca alkaloids, and taxanes. Dacarbazine treatment is the
gold standard for melanoma therapy. However, the response
rate observed with single-agent dacarbazine chemotherapy
ranges from 15 to 25%. Chemotherapy for advanced
melanoma remains largely palliative, because survival times
after diagnosis are short. Despite numerous trials of pre-
viously unreported molecular targeting compounds, such as
sorafenib and combination regimens of a plethora of
chemotherapeutics, dacarbazine treatment remains the first-
line therapy.
There is an urgent need for new, more efficient therapeutic
compounds for the treatment of advanced melanoma. This
study shows that M8 is able to reduce metastasis and might
therefore be a promising new therapy option targeting
metastasis in malignant melanoma.
Lymphangiogenesis is known to enhance the metastatic
spread of melanoma and can predict melanoma metastasis to
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sentinel lymph nodes (Dadras et al., 2005). Therefore, we will
evaluate in further studies the influence of M8 on lymphan-
giogenesis as possible mechanism to inhibit metastasis to
distant lymph nodes.
As M8 cannot totally block spreading of melanoma, it will
be necessary to combine M8 with other therapeutic regimes.
In conclusion, M8 is a potent inhibitor of melanoma in vitro
and in vivo. Further studies regarding combination strategies
are warranted.
MATERIALS AND METHODS
Cell line and chemicals
M24met cells (kindly provided by Dr RA Reisfeld, Department of
Immunology, Scripps Research Institute, La Jolla, CA; (Mueller et al.,
1991)) and MKN28 (human tubular adenocarcinoma) were grown in
RPMI 1640 supplemented with 10% fetal bovine serum, 2mM
glutamine, and 50mgml1 gentamicin sulfate. The human melanoma
cell line, M24, was derived from a biopsy of a lymph node metastasis
and M24met was established from an invaded lymph node of a nude
mouse (Mueller et al., 1991). The human melanoma cell line 1205Lu
isolated of lung metastasis was cultivated as described previously
(Smalley et al., 2005). M8 was provided by the Department of
Pharmaceutical Chemistry, University of Vienna, Austria. Resveratrol
was purchased from Sigma-Aldrich GmbH (Vienna, Austria).
Compounds were frozen as 50 or 10mM stock solutions in DMSO
(Sigma-Aldrich) and diluted in RPMI to the final concentrations
indicated for individual experiments.
Isolation of patient-derived melanoma cell lines MCM1,
MCM19, and MLNM1
Tumor tissue was carefully dissected and minced with a scalpel.
Samples were incubated in Dispase (BD Biosciences, San Diego,
CA) and collagenase type I (Sigma, St Louis, MO) for 30minutes at
37 1C. Cells were washed in DMEM 10% fetal calf serum by
centrifugation at 400 g. The pellet was resuspended in DMEM 15%
fetal calf serum containing recombinant human basic fibroblast
growth factor (1 ngml1), Epidermal growth factor (0.5 ngml1),
insulin-like growth factor I (2 ngml1) (all from Sigma), and plated
on rat tail collagen I (Sigma) coated dishes. Melanoma cells were
grown at 37 1C and 5% CO2 atmosphere. Informed consent was
obtained from all donors of melanocytic lesions. This study
was approved by the ethics committee of the Medical University
of Vienna and was carried out in compliance with the Declaration of
Helsinki Principles protocol.
Cell proliferation assay
The CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI) was used according to the manufacturer’s
guidelines. In brief, M24met cells were plated in 96-well plates
(1,500 cells per well). After 24 hours, increasing concentrations of
M8 (6.25, 12.5, 50, and 100mM), resveratrol (6.25, 12.5, 50, and
100mM), or a solvent control (DMSO alone) were added. After 24,
48, and 72 hours, proliferation was measured by incubating cultures
with a solution of MTS and phenazine methosulfate (1:20) for 2 hours
at 37 1C. Absorbance was measured at 490 nm with an ELISA plate
reader.
In case of CellTiter-Glo Luminescent Cell Viability Assay
(Promega) multiwell plates compatible with the luminometer were
used. The cells were plated and treated as described above and
seeded in 100ml medium. Equal reagent of CellTiter-Glo Reagent
was used and the plate was shaken for 2minutes to induce cell lysis.
Before recording luminescence, the plate was incubated at room
temperature for 10minutes.
Immunohistochemical staining of the primary melanoma cells
Melanoma cells were grown on tissue culture chamber slides
(Nalge Nunc, Naperville, IL) and fixed in 4% formaldehyde. The
primary antibodies used in the study were HMB45, Melan A, S100
(Dako, Carpinteria, CA), Nestin (IBL, Fujioka, Japan), and p75NTR
(Sigma) all diluted 1:200 in phosphate-buffered saline (PBS). Control
slides were stained with IgG control antibodies (Dako). After
washing in PBS cells were incubated with the respective second-
step biotinylated antibodies (Vector Laboratories, Burlingame, CA)
diluted 1:400 in PBS. Following incubation with streptavidin–horser-
adish peroxidase (Novocastra, Newcastle upon Tyne, UK) immuno-
reaction was visualized with AEC substrate (3-amino-9-ethyl-
carbazol; DakoCytomation, Glostrup, Denmark) and counterstained
with Mayer’s hematoxylin (Sigma, St Louis, MO). The three primary
melanoma cells MCM1, MCM19, and MLNM1 stained positively
with the melanoma marker S100, Nestin, and p75NTR, whereas
only MCM19 stained positively for HMB45/Melan A (Supplementary
Figure S1).
Western blot
Cells were frozen in liquid nitrogen and lysed with lysis buffer
containing phosphatase and protease inhibitors as described
previously (Hoeller et al., 2005). Protein concentration was
measured by the Bradford method and equal amounts of protein
were loaded per lane. After SDS–PAGE (12%) and blotting on
polyvinylidene difluoride, membranes were incubated with the
following primary antibodies: caspase-3 (1:1,000; Cell Signaling,
Boston, MA), Bak, Cdk-2 (1:200), p21, p53ser37, p53ser15, p53
(1:200; all Santa Cruz Biotechnology, Santa Cruz, CA), MSH6
(1:500; Pharmingen, San Diego, CA), MSH2 (1mgml1; Pharmingen),
MLH1 (1mgml1; Pharmingen), and Rock-1 (1:2,000; Chemicon,
Billerica, MA). Binding of primary antibodies was visualized by
incubation with horseradish-peroxidase-conjugated secondary anti-
bodies (anti-mouse IgG or anti-rabbit IgG; both from Amersham,
Buckinghamshire, UK) followed by chemiluminescent visualization
with ECL (Amersham). The optical density of bands was quantified
with TotalLab software (Nonlinear Dynamics, Newcastle upon Tyne,
UK). Loading differences were corrected based on the protein content
of tubulin (mouse anti-tubulin mAb; Sigma-Aldrich) or actin (rabbit
anti-actin mAb; Sigma-Aldrich).
Cell-cycle analysis
Untreated or treated cells were harvested, washed with PBS, and
fixed in 70% ethanol on ice for 30minutes. RNase (20 mgml1;
Sigma) was added, cells were stained with 20 mgml1 propidium
iodide for 30minutes at 37 1C in the dark and analyzed by flow
cytometry. Cell-cycle distribution was quantified with the ModFIT LT
software (Verity Software House, Topsham, ME).
Apoptosis assay
Cells were harvested after 48 hours after seeding, washed with PBS,
adjusted to a cell density of 2 to 5 105 per ml, and resuspended in
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100ml binding buffer (10mM HEPES/NaOH (pH 7.4), 140mM NaCl,
2.5mM CaCl2). Cells were incubated with a mix of Annexin
V–phycoerythrin (PE) and 7-amino-actinomycin D (7-AAD) for
15minutes in the dark according to the manufacturer’s recommen-
dation (BD Biosciences, San Jose, CA). Binding buffer (400 ml) was
added and Annexin-V-positive cells were analyzed by flow
cytometry.
Comet assay
M24met cells were harvested by trypsinization and placed into
Eppendorf tubes (5 104 cells per 0.5ml per tube) followed by a
5-minute treatment with M8 (5–200 mM) or resveratrol (25–200mM).
Positive and solvent controls were treated with 100mM H2O2 and
0.4% DMSO, respectively. Cell viability at the time of assay was490%.
The comet assay was performed according to published guide-
lines (Tice et al., 2000). The comet assay is a sensitive method to
detect DNA strand breaks and alkali labile sites in individual cells as
DNA migrates under alkaline conditions in an electrical field toward
the anode. The extent of migration depends on the degree of DNA
damage and is represented in the tail moment. Briefly, after
treatment, cells were washed twice with cold PBS, suspended in
low-melting-point agarose (0.6%), and applied onto microscope
slides coated with a thin layer of 0.7% normal-melting-point agarose
(BIOzyme, Hameln, Germany). Slides further exposed overnight to
lysis buffer (2.5 M NaCl, 100mM EDTA, 10mM Tris, pH 10) were
rinsed with distilled water and placed into electrophoresis buffer
(300mM NaOH, 1mM Na2-EDTA, 10mM Tris, pH413) for
20minutes at 4 1C to allow the DNA to unwind before subjecting
the slides for 20minutes to electrophoresis. Slides were fixed in
methanol. Ethidium bromide (2 mgml1) was used for DNA staining.
The slides were examined with a fluorescence microscope (Nikon,
Melville, NY) equipped with an automated image analysis system
based on the public domain program NIH image analysis system
(Helma and Uhl, 2000). The extent of DNA migration indicative for
induced DNA damage was expressed as tail moment, a parameter
calculated from the percentage of DNA in the comet tail and the tail
length in mm (Tice et al., 2000). Experiments were set up in triplicate
and images of 50 randomly selected cells per experiment (total 150
cells) were analyzed.
Matrigel invasion assay
Matrigel assay (BD Biosciences, Bedford, MA) consists of a two-well
chamber system with a pore size of 9 mm of the upper chamber, large
enough to allow cells to migrate. A total of 5 104 M24met cells
were plated into the upper chamber. Treatment with 25mM M8 was
compared with resveratrol (25 mM) and solvent control. After 48 hours
nonmigrated cells were mechanically removed and the transmi-
grated cells on the lower side of the upper chamber were fixed in
70% ethanol and stained using 0.2% crystal blue. Pictures were
captured with a confocal laser microscope (Zeiss, Vienna, Vienna,
Austria) and the relative amount of transmigrated cells was
quantified with a computer-assisted analysis system (AxioVision).
Proteome analysis
Shotgun analysis was performed as described previously (Paulitschke
et al., 2009; Wimmer et al., 2009). For isolation of cytoplasm
fractions of M24met and 1205Lu cells (control and 25mM M8), we
washed the cells after treatment. The cell supernatant was collected,
sterile filtrated to remove cellular debris, and precipitated by the
addition of ethanol. For the isolation of cytoplasmic proteins, we
supplemented all buffers with protease inhibitors. Cells were lysed in
hypotonic lysis buffer and pressed through a 26-gauge syringe to
open the cells by rupture. The cytoplasmic fraction was separated
from the nuclei by centrifugation and precipitated by the addition of
ethanol. All protein samples were dissolved in sample buffer (7.5 M
urea, 1.5 M thiourea, 4% CHAPS, 0.5% SDS, and 100mM DDT).
For shotgun analysis, peptides were separated by nanoflow LC
(1100 Series LC System; Agilent, Palo Alto, CA) using the HPLC-Chip
technology (Agilent) equipped with a 40 nl Zorbax 300SB-C18
trapping column and a 75 mm 150mm Zorbax 300SB-C18 separa-
tion column at a flow rate of 400 nlmin1, using a gradient from
0.2% formic acid and 3% acetonitrile to 0.2% formic acid and 50%
acetonitrile for 60minutes. Peptide identification was accomplished
by MS/MS fragmentation analysis with an ion trap mass spectrometer
(XCT-Ultra; Agilent) equipped with an orthogonal nanospray ion
source. The MS/MS data were interpreted by the Spectrum Mill MS
Proteomics Workbench software (version A.03.03; Agilent) and
searched against the SwissProt Database (version 14.3 containing
20,328 protein entries) allowing for precursor mass deviation of
1.5Da, a product mass tolerance of 0.7Da, and a minimum
matched peak intensity (%SPI) of 70%. Owing to previous chemical
modification, carbamidomethylation of cysteines was set as fixed
modification.
Spontaneously metastatic human melanoma mouse model
Pathogen-free, 4- to 6-week-old female CB17 scid/scid (severe
combined immunodeficient, SCID) mice (Charles River, Sulzfeld,
Germany) were housed and treated as described (Kunstfeld et al.,
2003). M24met cells (2 106) were injected subcutaneously in the
flank of SCID mice. After clinical appearance of tumors, mice were
treated every day with M8 (2.5mg kg1 once or twice a day), M8
(5mg kg1 once or twice a day), or solvent control. Tumors were
measured with calipers and tumor volumes were calculated using
the formula (a2 b)/2, with a being the width and b the length of the
tumor. When tumors reached a size of approximately 900mm3,
commonly 14–18 days after injection, animals were anesthetized,
the primary tumors removed, and skin defects were sutured. The
treatment schedule was continued for 10 days. After this period mice
were killed and examined for metastasis.
Two mouse experiments were performed. In the first experiment
we evaluated tumor volume in the control group (n¼ 7) compared to
the treated groups (n¼ 9 in the 2.5mg kg1 per day group, n¼ 8 in
the 5mg kg1 per day group). In the second mouse experiment we
also evaluated spontaneous metastasis to the distant lymph nodes
beside tumor volume. In this approach we used 10 mice for each
group.
One piece of the removed tumor was used for tumor cell
isolation. The tumor was swabbed with ethanol, washed in PBS, cut
in 4mm slices, and transferred to RPMI 1640 tissue culture medium.
All procedures were carried out in line with the guidelines of the
Association for Assessment and Accreditation of Laboratory Animal
Care and The Guide for the Care and Use of Laboratory Animals
(Department of Health and Human Services, National Institutes of
Health). All experiments were approved by the animal welfare
committee of the Medical University of Vienna and the Austrian
Government Committee on Animal Experimentation.
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Histology and immunohistochemistry of melanomas
and lymph nodes
Paraffin-embedded primary melanomas and lymph nodes were
stained with hematoxylin and eosin according to standard proce-
dures as described previously (Loewe et al., 2006) for detection of
macrometastasis.
For immunohistochemistry, slides were incubated with mouse
anti-human Ki-67 antibody (Beckman Coulter, Fullerton, CA),
followed by incubation with a biotinylated anti-mouse antibody
(Vector Laboratories). Images were captured with a confocal
laser microscope (Zeiss) and field percent of Ki-67-positive
cells were quantified with a computer-assisted analysis system
(AxioVision).
For the detection of micrometastasis in axillary and inguinal
lymph nodes, staining was performed in a DAKO TechMate Horizon
automated staining system according to the manufacturer’s protocol.
Serial sections were incubated with a monoclonal anti-human
vimentin antibody (clone V9). This mAb selectively recognizes
human vimentin and therefore distinguishes human melanoma cells
from neighboring mouse tissue. Reactivity of mAb V9 was visualized
with a biotinylated anti-rabbit antibody (DakoCytomation), strepta-
vidin and horseradish-peroxidase-conjugate (DakoCytomation), and
AEC (DakoCytomation).
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